Tesetaxel as First-line Therapy for Metastatic Breast Cancer
The intravenously administered taxane, paclitaxel, is one of the most commonly employed agents for the treatment of both localized and advanced breast cancer.

Tesetaxel is an orally administered taxane that is in development as first- and second-line treatment for patients with advanced cancers. This study is being undertaken to determine the efficacy and safety of tesetaxel administered as first-line therapy to patients with metastatic breast cancer.
Breast Neoplasm
DRUG: Tesetaxel once every 3 weeks|DRUG: Tesetaxel once weekly
Response rate (revised RECIST), Proportion of patients with a confirmed complete or partial response, 12 months from date of first dose of study medication for last patient enrolled
Disease control rate, Proportion of patients with a confirmed complete or partial response of any duration or stable disease ≥ 3 months in duration, 12 months from date of first dose of study medication for last patient enrolled|Progression-free rate, Proportion of patients without disease progression 6 months following the first dose of study medication, 6 months from date of first dose of study medication for last patient enrolled|Durable response rate, Proportion of patients with a confirmed complete or partial response ≥ 6 months in duration, 12 months from date of first dose of study medication for last patient enrolled|Duration of response, Date when response criteria are first met to the date when progression is first documented, 12 months from date of first dose of study medication for last patient enrolled|Time to progression, Date of first dose of study medication to the date when progression is first documented, 12 months from date of first dose of study medication for last patient enrolled|Adverse events, Incidence of adverse events, Up to 30 days after the last dose of study medication for a specific patient
The intravenously administered taxane, paclitaxel, is one of the most commonly employed agents for the treatment of both localized and advanced breast cancer.

Tesetaxel is an orally administered taxane that is in development as first- and second-line treatment for patients with advanced cancers. This study is being undertaken to determine the efficacy and safety of tesetaxel administered as first-line therapy to patients with metastatic breast cancer.